AccessEAP is an Australian owned and not-for-profit organisation with over 30 years in the EAP industry, and founding members of the EAP industry in Australia. Engaged to provide a multidimensional, commercial view to strategic oversight, provide expertise in government and external affairs and challenge assumptions, in order to uncover opportunities to maximise organisational execution. Additionally, member of the Remuneration & Nominations Committee.

Vita Sci Consulting, established in 2022, provides strategic advisory services for the life sciences, biotechnology, diagnostics, and healthcare industries. We specialise in strategy formulation, commercialisation, and global market entry.Client engagements include:• Client Consulting: Advise multinational and start-up organisations on market entry assessments, strategy development, tender responses, and multi-million dollar engagements.• Strategy and Commercialisation: Guide IP owners on market entry strategies and create marketing plans to attract investment and secure funding.• Mentoring Start-ups: Mentor biotechnology startups through IP commercialisation, helping them navigate complex market dynamics and regulatory environments.• Investment Facilitation: Identify and facilitate introductions between IP owners and funding sources (venture capitalists, family offices etc).• Go-to-Market Strategy: Develop GTM strategies, identify key opinion leaders, and establish relationships with specialist providers for successful product launches in Australia, New Zealand, Asia, and North America.• Global Launch: Execute global market entry strategies, building relationships with key opinion leaders and specialist providers worldwide.• Industry Insights: Provide insights to investment bank and stock analysts on ASX-listed biotech companies, coaching analysts on evaluating biotech stocks. Act as an industry expert for investment bank forums with client investors.• Government Collaboration: Work with industry associations and government departments to improve the translation of Australian IP into commercial outcomes.

Provide governance and oversight on all aspects of the business, ensuring alignment with pre-described strategic imperatives, asking detailed questions, providing insights based on observations to ensure the business is run in an optimal manner.

Joining Abbott as a commercial lead to gain deep APAC experience, my focus is organizational - aligning APAC commercial and operational execution with APAC Strategy, liaising with country general managers and their teams to ensure consistent commercial execution, and building capability not only in-region but across our clients in matters related to effective business execution. Bringing a fresh perspective and genuine customer obsession to the table, my impact has really been to influence a shift from product/ tactical based execution to more of a strategic, solutions-focused approach, centring account management on the creation of deep business relationships that yield substantial customer and business benefits into the future. Examples of this include aligning customer ESG agenda with our offerings to align and augment their business goals.

Pathology Technology Australia (PTA) represents Australian sponsors, manufacturers and distributors of in-vitro diagnostics and innovative pathology technology. Played a transformational role in gaining board support and establish an assertive strategy to increase the industries relevance to the Australian health system. This involved leading intensive stakeholder consultation and facilitation to realign strategy and reengineer PTA’s raison d'etre and better articulate and increase PTA’s voice in accelerating the rapid adoption of innovative technologies by the Australian health system, for improved economic and health outcomes for Australian patients. One of the most notable outcomes is the recognition by the Australian government and media of PTA as an organisation sought out for advice during the pandemic. Through advocacy work and partnerships with leading epidemiologists, PTA played an integral role in the acceptance of rapid antigen test for COVID-19 by the government.

Leveraging strong experience in the diagnostics industry to lead commercialisation and launch in the United States, China and Australia, I prepared and delivered a complete GTM strategy for an innovative start-up, securing the support of more than 40 doctors and Key Opinion Leaders. I recruited third-party organisations to operationalise new routes to market, establishing the logistical and infrastructure support to receive the sample, perform the test and report the results to requesting physicians. I also acquired new funding sources and encouraged a large Australian private pathology provider to administer the test on a patient-pay basis, a key example of first-to-market innovation.

Recruited by Roche to orchestrate a major transformation, involving the development of a highly nuanced and specific business growth strategy and change plan considering all elements of business operations and culture. Working closely with HR to craft and share a compelling message to the wider team, within 4 weeks of joining the team I drafted a workable strategic plan to boost revenue and profits, driving achievement of all revenue and profitability targets within 18 months. Surpassing expectations and profitability targets, I am immensely proud of the team’s contribution and the revitalisation of culture and engagement, providing a solid platform for sustained growth into the future.

Provided transformational leadership to 35+ people in marketing, IT support, project management, clinical nurse educators, medical liaison officer and other roles, aligning two businesses into one organisation set up for growth in the face of changing market trends. I led and delivered the mandated transformation initiative, operationalising one GTM model with no significant disruption in productivity, while running two P&Ls at the same time, managing expectations across different business units and in a matrix business structure while empowering the new unified team to set the standard for a larger and more dynamic business over the next 5 years. I grew the business and returned profitability as a greater percentage of sales with every successive year, earning Greater Asia Business Director of the Year for 2014 and 2016.